Cancer Chemotherapy and Pharmacology

Article	Citations
Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma	99
Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers	29
Roles of DNA polymerase ζ in the radiotherapy sensitivity and oxidative stress of lung cancer cells	26
Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors	23
New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis	23
A polo-like kinase 1 inhibitor enhances erastin sensitivity in head and neck squamous cell carcinoma cells in vitro	23
PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma	21
Disulfiram enhances chemotherapeutic effects of doxorubicin liposomes against human hepatocellular carcinoma via activating ROS-induced cell stress response pathways	21
Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma	21
Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1	21
Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma	20
Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug–drug interactions	20
Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [14C] SHC014748M in healthy Chinese subjects following oral administration	20
A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors	19
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors	19
Determination of 5-azacitidine in human plasma by LC–MS/MS: application to pharmacokinetics pilot study in MDS/AML patients	18
Comparison of the immunomodulatory potential of platinum-based anti-cancer drugs and anthracyclins on human monocyte-derived cells	18
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations	17
Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor	16
External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data	16
A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis	16
Assay performance and stability of uracil and dihydrouracil in clinical practice	15
Quantitative proteomics profiling reveals the inhibition of trastuzumab antitumor efficacy by phosphorylated RPS6 in gastric carcinoma	14
Tumor-associated macrophages promote cisplatin resistance in ovarian cancer cells by enhancing WTAP-mediated N6-methyladenosine RNA methylation via the CXCL16/CXCR6 axis	14
Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients	14

The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models	13
Oral docetaxel plus encequidar – a phase 1 clinical trial	13
Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer	13
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study	13
An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors	13
Cardioprotective potential of mitochondria-targeted antioxidant, mito-TEMPO, in 5-fluorouracil-induced cardiotoxicity	13
Removal rate of 5-fluorouracil and its metabolites in patients on hemodialysis: a report of two cases of colorectal cancer patients with end-stage renal failure	13
The landscape of very important pharmacogenes variants and potential clinical relevance in the Chinese Jingpo population: a comparative study with worldwide populations	13
The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers	12
Acute kidney injury in a child treated with cisplatin and amphotericin B	12
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)	12
Absorption, single-dose and steady-state metabolism, excretion, and pharmacokinetics of adagrasib, a KRASG12C inhibitor	12
Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with 4hydroxycyclophosphamide formation in children with Cancer	12
Correction to: PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1	11
Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2– advanced breast cancer in Chinese women	11
Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma	11
Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease	11
EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer	11
Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management	11
Use of cucurbitacins for lung cancer research and therapy	11
Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma	11
Tissue distribution of epirubicin after severe extravasation in humans	11
Influence of FPGS, ABCC4, SLC29A1, and MTHFR genes on the pharmacogenomics of fluoropyrimidines in patients with gastrointestinal cancer from the Brazilian Amazon	11
Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6–Cyclin D–Rb pathway	11
Correlation between pharmacokinetic parameters of 5-fluorouracil and related metabolites and adverse reactions in East-Asian patients with advanced colorectal cancer	10
Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors	10
Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study	10
A clinical scoring tool validated with machine learning for predicting severe hand–foot syndrome from sorafenib in hepatocellular carcinoma	10
Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission	10
Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck	10
Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model‐based population pharmacokinetic analysis	10
A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies	10
Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression	10
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers	10
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship	10
Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study	9
Pharmacokinetic analysis of crushed venetoclax tablets combined with azacitizine for recurrent pediatric acute myeloid leukemia (AML)	9
Repurposed antipsychotic chlorpromazine inhibits colorectal cancer and pulmonary metastasis by inducing G2/M cell cycle arrest, apoptosis, and autophagy	9
A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or rela	9
Correction to: Apoptosis of murine melanoma B16-BL6 cells induced by quercetin targeting mitochondria, inhibiting expression of PKC-α and translocating PKC-δ	9
Mass spectroscopy-based proteomics and metabolomics analysis of triple-positive breast cancer cells treated with tamoxifen and/or trastuzumab	9
Translational model of melphalan-induced gut toxicity reveals drug-host-microbe interactions that drive tissue injury and fever	9
Downregulation of SELENBP1 enhances oral squamous cell carcinoma chemoresistance through KEAP1–NRF2 signaling	9
Cardiovascular toxicity of breast cancer treatment: an update	9
An exposure–safety analysis to support the dosage of the novel AKT inhibitor capivasertib	8
Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study	8
Absorption, metabolism and excretion of [14C]-sotorasib in healthy male subjects: characterization of metabolites and a minor albumin-sotorasib conjugate	8
Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy	8
Combination of ionizing radiation and 2-thio-6-azauridine induces cell death in radioresistant triple negative breast cancer cells by downregulating CD151 expression	8
A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia	8

Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors	8
AKR1C4 regulates the sensitivity of colorectal cancer cells to chemotherapy through ferroptosis modulation	8
Using maximum plasma concentration (Cmax) to personalize taxane treatment and reduce toxicity	8
Cabozantinib-induced serum creatine kinase elevation and rhabdomyolysis: a retrospective case series	8
A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome	8
Time-dependent population PK models of single-agent atezolizumab in patients with cancer	8
Phase 2 study of glucarpidase in patients with delayed methotrexate elimination after high-dose methotrexate therapy	8
PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer	8
Influence of DPYD gene polymorphisms on 5-Fluorouracil toxicities in Thai colorectal cancer patients	8
Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer	8
Development of a novel nomogram for predicting delayed methotrexate excretion following high-dose methotrexate in adult patients with hematologic malignancies	8
Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma	8
The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis	8
Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer	7
Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children’s Research Hospital	7
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study	7
Azithromycin inhibits glioblastoma angiogenesis in mice via inducing mitochondrial dysfunction and oxidative stress	7
Bidirectional pharmacokinetic drug interactions between olaparib and metformin	7
Sodium orthovanadate exhibits anti-angiogenic, antiapoptotic and blood glucose-lowering effect on colon cancer associated with diabetes	7
Preventive effect of free radical scavenger edaravone lotion on cyclophosphamide chemotherapy-induced alopecia	7
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors	7
Plasma clearance of 5-fluorouracil is more influenced by variations in glomerular filtration rate than by uracil concentration	7
Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study	7
Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide	7
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma	7
Translational PK-PD/TD modeling of antitumor effects and peripheral neuropathy in gemcitabine and nab-paclitaxel chemotherapy from xenograft mice to patients for optimal dose and schedule	7
Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report	7
Gene polymorphisms of TACR1 serve as the potential pharmacogenetic predictors of response to the neurokinin-1 receptor antagonist-based antiemetic regimens: a candidate-gene association study in breas	7
Andrographolide inhibits Burkitt’s lymphoma by binding JUN and CASP3 proteins	7
Parthenolide inhibits the proliferation and migration of cervical cancer cells via FAK/GSK3β pathway	7
Enhanced anticancer synergy of LOM612 in combination with selinexor: FOXO1 nuclear translocation-mediated inhibition of Wnt/β-catenin signaling pathway in breast cancer	7
Long non-coding RNAs: controversial roles in drug resistance of solid tumors mediated by autophagy	7
Are novel oral oncolytics underdosed in obese patients?	7
Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells	7
Phase I–II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors	6
Glaucocalyxin A induces apoptosis and autophagy in tongue squamous cell carcinoma cells by regulating ROS	6
Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic–pharmacodynamic real-life study	6
Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study	6
Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review	6
Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells	6
A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects	6
Prospective clinical trial testing COXEN-based gene expression models of chemosensitivity in dogs with spontaneous osteosarcoma	6
Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children’s Oncology Group Study ADVL06B1	6
Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation	6
Evaluation of urinary vanin-1 for the early prediction of cisplatin-induced acute kidney injury during neoadjuvant chemotherapy for esophageal cancer	6
UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells	6
Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice	6
Population pharmacokinetics of crenolanib in children and young adults with brain tumors	6
Somatic nuclear auto-antigenic sperm protein sensitizes human breast cancer cells to 5-Fluorouracil	6
Selinexor targeting XPO1 promotes PEG3 nuclear accumulation and suppresses cholangiocarcinoma progression	6
Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability	6
Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway	6
Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib	6
Ex-vivo activation of a liposomal prodrug of mitomycin C by human tumors	6
Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review	6
Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway	6
Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations	5
The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent	5
Is age just a number? A population pharmacokinetic study of gemcitabine	5
Exposure–response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma	5
Retraction Note to: MicroRNA‑30c‑regulated HDAC9 mediates chemoresistance of breast cancer	5
Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants	5
Pharmacology and pharmacokinetics of elacestrant	5
Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients	5
Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients	5
Effect of massive ascites on ramucirumab pharmacokinetics in patients with gastrointestinal cancers: a population pharmacokinetic analysis	5
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial	5
Value of whole-body dynamic 18F-FMISO PET/CT Patlak multi-parameter imaging for evaluating the early radiosensitizing effect of oleanolic acid on C6 rat gliomas	5
Pharmacokinetics and clinical outcomes of low-dose nivolumab relative to conventional dose in patients with advanced cancer	5
MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism	5
Editorial Expression of Concern for: Induction of apoptosis by [6]-gingerol associated with the modulation of p53 and involvement of mitochondrial signaling pathway in B[a]P-induced mouse skin tumorig	5
Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer	5
Re-thinking the possible interaction between proton pump inhibitors and capecitabine	5
Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer	5
An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16	5
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors	5
A bioequivalence study of trifluridine/tipiracil tablets in Chinese metastatic colorectal cancer patients under fed conditions	5
Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic–pharmacodynamic model of neutropenia	5
Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies	5
Anti-cancer drug combinations approved by US FDA from 2011 to 2021: main design features of clinical trials and role of pharmacokinetics	5

Role of renin angiotensin system inhibitors and metformin in Glioblastoma Therapy: a review	5
Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells	5
Zileuton inhibits arachidonate-5-lipoxygenase to exert antitumor effects in preclinical cervical cancer models	5
The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update	5
Comment on “Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase”	4
Multicenter randomized phase II study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases (YCOG1001)	4
Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug	4
Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants	4
Megestrol acetate is a specific inducer of CYP3A4 mediated by human pregnane X receptor	4
Retraction Note: NO donor inhibits proliferation and induces apoptosis by targeting PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma cells	4
Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma	4
Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults	4
RETRACTED ARTICLE: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment	4
A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors	4
Life-threatening toxicities upon Pembrolizumab intake: could pharmacokinetics be the bad guy?	4
Minimal PK/PD model for simultaneous description of the maximal tolerated dose and metronomic treatment outcomes in mouse tumor models	4
Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas	4
Effect of carboplatin dose capping on survival in recurrent breast, ovary and head and neck cancers: a single institutional retrospective study	4
Absorption, metabolism, and excretion of oral [14C] radiolabeled donafenib: an open-label, phase I, single-dose study in humans	4
Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice—a prospective single-center trial	4
Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19	4
Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case–control study	4
Impact of bariatric surgery on oral anticancer drugs: an analysis of real-world data	4
Upregulation of TRIB2 by Wnt/β-catenin activation in BRAFV600E papillary thyroid carcinoma cells confers resistance to BRAF inhibitor vemurafenib	4
Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer	4
Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia	4
Alterations in pharmacogenetic genes and their implications for imatinib resistance in Chronic Myeloid Leukemia patients from an admixed population	4
An exploration of the impact of ethanol diluent on breath alcohol concentration in patients receiving paclitaxel chemotherapy	4
Correction to: Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy	4
A minimal physiologically based pharmacokinetic model for high-dose methotrexate	4
Pharmacology and pharmacokinetics of tazemetostat	4
Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms	4
A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patients	4
Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase	4
Correction to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants	4
Predictive value of ERCC2, ABCC2 and MMP2 of response and long-term survival in locally advanced head and neck cancer patients treated with chemoradiotherapy	4
4-(N)-Docosahexaenoyl 2’, 2’-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent	3
Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India	3
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study	3
Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer	3
Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection	3
Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis	3
Plasma endothelin-1 may predict bevacizumab-induced proteinuria in patients with colorectal cancer	3
Introducing a simple and cost-effective RT-PCR protocol for detection of DPYD*2A polymorphism: the first study in Kurdish population	3
Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leuke	3
Anti-drug antibodies in the current management of cancer	3
Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti–programmed cell death protein-1 (PD-1) antibody, in human cancer models	3
Effects of splicing-regulatory polymorphisms in ABCC2, ABCG2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemia	3
Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy	3
Landscape analysis of adverse events and dose intensity for FDA approved oncology small molecules	3
Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment	3
Ruthenium–dihydroartemisinin complex: a promising new compound for colon cancer prevention via G1 cell cycle arrest, apoptotic induction, and adaptive immune regulation	3
Correction to: A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C	3
Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report	3
Precision fluoropyrimidines dosing in a compound heterozygous variant carrier of the DPYD gene: a case report	3
A bavachinin analog, D36, induces cell death by targeting both autophagy and apoptosis pathway in acute myeloid leukemia cells	3
Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical s	3
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial	3
The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia	3
PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials	3
A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese ma	3
Pharmacokinetics and pharmacodynamics of Rh2 and aPPD ginsenosides in prostate cancer: a drug interaction perspective	3
A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer	3
The role of alternative splicing in lung cancer	3
Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats	3
Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer	3
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies	3
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast canc	3
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors	2
Optimized scaling of translational factors in oncology: from xenografts to RECIST	2
Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach	2
Efficacy and safety exposure–response analyses of entrectinib in patients with advanced or metastatic solid tumors	2
Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point	2
Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites	2
Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma	2
A phase I study of the ceramide nanoliposome in patients with advanced solid tumors	2
Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients	2
Targeted therapy of angiogenesis using anti-VEGFR2 and anti-NRP-1 nanobodies	2
A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies	2
Mouse pharmacokinetics and metabolism of the phenylurea thiocarbamate NSC 161128	2
Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma	2
Nanotechnology and nanobots unleashed: pioneering a new era in gynecological cancer management – a comprehensive review	2
The use of vitamin E in preventing taxane-induced peripheral neuropathy	2
Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model	2
Targeting on the PI3K/mTOR: a potential treatment strategy for clear cell ovarian carcinoma	2
Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study	2
Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)	2
Oncology dose optimization paradigms: knowledge gained and extrapolated from approved oncology therapeutics	2
Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors	2
Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer	2
A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma	2
Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis	2
Phase I study of tamibarotene monotherapy in pediatric and young adult patients with recurrent/refractory solid tumors	2
DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy	2
Hsp90 inhibition sensitizes DLBCL cells to cisplatin	2